Medicamen Biotech Limited (MEDICAMEQ.BO)
INR 492.5
(6.9%)
INR 492.5
(6.9%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 495.49 Million INR | -27.95% |
| 2022 | 687.74 Million INR | 9.01% |
| 2021 | 630.9 Million INR | 88.24% |
| 2020 | 335.16 Million INR | -4.33% |
| 2019 | 350.34 Million INR | 11.52% |
| 2018 | 314.15 Million INR | -4.0% |
| 2017 | 327.24 Million INR | 26.49% |
| 2016 | 258.71 Million INR | 40.51% |
| 2015 | 184.13 Million INR | -5.84% |
| 2014 | 195.55 Million INR | 5.73% |
| 2013 | 184.95 Million INR | 31.66% |
| 2012 | 140.47 Million INR | -31.07% |
| 2011 | 203.78 Million INR | -11.05% |
| 2010 | 229.11 Million INR | -7.45% |
| 2009 | 247.56 Million INR | 40.74% |
| 2008 | 175.9 Million INR | 1.78% |
| 2007 | 172.82 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 93.51 Million INR | -31.02% |
| 2023 FY | 495.49 Million INR | -27.95% |
| 2023 Q1 | 210.76 Million INR | 23.86% |
| 2023 Q2 | 203.89 Million INR | -3.26% |
| 2023 Q3 | 215.19 Million INR | 5.54% |
| 2023 Q4 | 135.56 Million INR | -37.0% |
| 2022 FY | 687.74 Million INR | 9.01% |
| 2022 Q4 | 170.15 Million INR | -8.53% |
| 2022 Q3 | 186.03 Million INR | 9.68% |
| 2022 Q2 | 169.61 Million INR | 4.74% |
| 2022 Q1 | 161.93 Million INR | 665.85% |
| 2021 Q2 | 186.64 Million INR | 22.38% |
| 2021 FY | 630.9 Million INR | 88.24% |
| 2021 Q3 | 169.34 Million INR | -9.27% |
| 2021 Q1 | 152.51 Million INR | 756.1% |
| 2021 Q4 | -28.61 Million INR | -116.9% |
| 2020 Q1 | 94.2 Million INR | 959.03% |
| 2020 Q2 | 115.94 Million INR | 23.07% |
| 2020 Q3 | 107.19 Million INR | -7.55% |
| 2020 Q4 | 17.81 Million INR | -83.38% |
| 2020 FY | 335.16 Million INR | -4.33% |
| 2019 FY | 350.34 Million INR | 11.52% |
| 2019 Q2 | 128.68 Million INR | 25.11% |
| 2019 Q3 | 129.76 Million INR | 0.84% |
| 2019 Q1 | 102.85 Million INR | 17693.49% |
| 2019 Q4 | -10.96 Million INR | -108.45% |
| 2018 Q4 | 578.07 Thousand INR | -99.4% |
| 2018 Q2 | 109.3 Million INR | 1.23% |
| 2018 FY | 314.15 Million INR | -4.0% |
| 2018 Q1 | 107.96 Million INR | 1203.71% |
| 2018 Q3 | 96.31 Million INR | -11.88% |
| 2017 Q2 | 112.29 Million INR | 9.74% |
| 2017 Q3 | 122.41 Million INR | 9.01% |
| 2017 Q4 | -9.78 Million INR | -107.99% |
| 2017 FY | 327.24 Million INR | 26.49% |
| 2017 Q1 | 102.32 Million INR | 437.61% |
| 2016 Q1 | 71.77 Million INR | 316.81% |
| 2016 FY | 258.71 Million INR | 40.51% |
| 2016 Q4 | 19.03 Million INR | -76.91% |
| 2016 Q2 | 86.29 Million INR | 20.23% |
| 2016 Q3 | 82.44 Million INR | -4.47% |
| 2015 FY | 184.13 Million INR | -5.84% |
| 2015 Q3 | 48.79 Million INR | -21.6% |
| 2015 Q4 | 17.22 Million INR | -64.71% |
| 2015 Q2 | 62.23 Million INR | 11.36% |
| 2015 Q1 | 55.88 Million INR | 1544.2% |
| 2014 Q4 | -3.86 Million INR | -105.97% |
| 2014 Q1 | 61.49 Million INR | 523.05% |
| 2014 Q2 | 73.15 Million INR | 18.96% |
| 2014 FY | 195.55 Million INR | 5.73% |
| 2014 Q3 | 64.77 Million INR | -11.45% |
| 2013 Q3 | 44.6 Million INR | -35.36% |
| 2013 Q2 | 69 Million INR | 12.23% |
| 2013 Q4 | 9.86 Million INR | -77.87% |
| 2013 FY | 184.95 Million INR | 31.66% |
| 2013 Q1 | 61.48 Million INR | 954.29% |
| 2012 Q2 | 57.72 Million INR | 42.97% |
| 2012 Q4 | 5.83 Million INR | -84.04% |
| 2012 FY | 140.47 Million INR | -31.07% |
| 2012 Q1 | 40.37 Million INR | 92.59% |
| 2012 Q3 | 36.54 Million INR | -36.68% |
| 2011 Q4 | 20.96 Million INR | -67.85% |
| 2011 FY | 203.78 Million INR | -11.05% |
| 2011 Q2 | 117.61 Million INR | 0.0% |
| 2011 Q3 | 65.2 Million INR | -44.56% |
| 2010 FY | 229.11 Million INR | -7.45% |
| 2009 FY | 247.56 Million INR | 40.74% |
| 2008 FY | 175.9 Million INR | 1.78% |
| 2008 Q4 | 53.23 Million INR | 0.0% |
| 2007 FY | 172.82 Million INR | 0.0% |
| 2007 Q4 | 57.68 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 98.15% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.68% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 96.015% |
| Granules India Limited | 16.79 Billion INR | 97.05% |
| Indoco Remedies Limited | 6.04 Billion INR | 91.798% |
| Achyut Healthcare Limited | 4.86 Million INR | -10093.273% |
| Ajanta Pharma Limited | 21.06 Billion INR | 97.648% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.053% |
| Alpa Laboratories Limited | 188.89 Million INR | -162.312% |
| Brooks Laboratories Limited | 65.62 Million INR | -655.098% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 92.037% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 66.334% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 86.592% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.697% |
| Eris Lifesciences Limited | 10.42 Billion INR | 95.248% |
| FDC Limited | 8.33 Billion INR | 94.055% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.285% |
| Gufic Biosciences Limited | 4.16 Billion INR | 88.111% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 92.001% |
| Ipca Laboratories Limited | 29.8 Billion INR | 98.338% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 24.073% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -157.097% |
| Lasa Supergenerics Limited | 121.02 Million INR | -309.398% |
| Laurus Labs Limited | 24.62 Billion INR | 97.987% |
| Lupin Limited | 123.71 Billion INR | 99.599% |
| Mankind Pharma Limited | 44.52 Billion INR | 98.887% |
| Medico Remedies Limited | 262.14 Million INR | -89.016% |
| Megasoft Limited | 342.07 Million INR | -44.852% |
| NATCO Pharma Limited | 25.73 Billion INR | 98.075% |
| Piramal Pharma Limited | 24.47 Billion INR | 97.975% |
| RPG Life Sciences Limited | 2.48 Billion INR | 80.045% |
| Sigachi Industries Limited | 2 Billion INR | 75.253% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.808% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 87.983% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 47.422% |
| Unichem Laboratories Limited | 4.86 Billion INR | 89.815% |
| Wanbury Limited | 1.73 Billion INR | 71.369% |
| Windlas Biotech Limited | 1.33 Billion INR | 62.99% |
| ZIM Laboratories Limited | 1.26 Billion INR | 60.889% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.604% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 182.253% |
| Divi's Laboratories Limited | 32.44 Billion INR | 98.473% |
| Hester Biosciences Limited | 1.27 Billion INR | 61.096% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 91.429% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 68.167% |
| Bal Pharma Limited | 770.19 Million INR | 35.666% |
| Strides Pharma Science Limited | 14.38 Billion INR | 96.556% |
| Venus Remedies Limited | 2.18 Billion INR | 77.298% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 91.503% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 83.328% |
| Shilpa Medicare Limited | 3.54 Billion INR | 86.03% |
| Aarti Drugs Limited | 8.31 Billion INR | 94.042% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 89.183% |
| Suven Life Sciences Limited | -200.79 Million INR | 346.764% |
| Ind-Swift Limited | 2.17 Billion INR | 77.193% |
| Valiant Laboratories Limited | -60.66 Million INR | 916.786% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 97.817% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 42.465% |
| Themis Medicare Limited | 1.5 Billion INR | 67.053% |
| Hikal Limited | 3.14 Billion INR | 84.235% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.94% |
| Sequent Scientific Limited | 2.97 Billion INR | 83.366% |
| Novartis India Limited | 1.32 Billion INR | 62.658% |
| Wockhardt Limited | 16.24 Billion INR | 96.949% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 97.477% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -3298.527% |
| Neuland Laboratories Limited | 8.24 Billion INR | 93.992% |
| Morepen Laboratories Limited | 6.16 Billion INR | 91.958% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 20.143% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 29.578% |